These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11158013)

  • 1. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.
    Muller AF; Janssen JA; Hofland LJ; Lamberts SW; Bidlingmaier M; Strasburger CJ; van der Lely AJ
    J Clin Endocrinol Metab; 2001 Feb; 86(2):590-3. PubMed ID: 11158013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.
    Muller AF; Janssen JA; Lamberts SW; Bidlingmaier M; Strasburger CJ; Hofland L; van der Lely AJ
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):461-7. PubMed ID: 11678828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects.
    Moller L; Norrelund H; Jessen N; Flyvbjerg A; Pedersen SB; Gaylinn BD; Liu J; Thorner MO; Moller N; Lunde Jorgensen JO
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4524-32. PubMed ID: 19820031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ghrelin drives GH secretion during fasting in man.
    Muller AF; Lamberts SW; Janssen JA; Hofland LJ; Koetsveld PV; Bidlingmaier M; Strasburger CJ; Ghigo E; Van der Lely AJ
    Eur J Endocrinol; 2002 Feb; 146(2):203-7. PubMed ID: 11834429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
    Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.
    Muller AF; Leebeek FW; Janssen JA; Lamberts SW; Hofland L; van der Lely AJ
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5165-71. PubMed ID: 11701672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.
    Van Dam PS; Smid HE; de Vries WR; Niesink M; Bolscher E; Waasdorp EJ; Dieguez C; Casanueva FF; Koppeschaar HP
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4706-11. PubMed ID: 11134132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of free fatty acids, growth hormone and growth hormone receptor blockade on serum ghrelin levels in humans.
    Gormsen LC; Nielsen C; Gjedsted J; Gjedde S; Vestergaard ET; Christiansen JS; Jørgensen JO; Møller N
    Clin Endocrinol (Oxf); 2007 May; 66(5):641-5. PubMed ID: 17492951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
    Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone receptor antagonist treatment reduces exercise performance in young males.
    Goto K; Doessing S; Nielsen RH; Flyvbjerg A; Kjaer M
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3265-72. PubMed ID: 19549743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
    Catalina PF; Mallo F; Andrade MA; García-Mayor RV; Diéguez C
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3663-7. PubMed ID: 9768681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
    Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
    J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women.
    Anderson SM; Shah N; Evans WS; Patrie JT; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):551-60. PubMed ID: 11158008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
    McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
    J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
    Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
    Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.